The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months
Open accessAbstract
There is little published information regarding treatment completion, safety, and efficacy of rifampin administered daily for 4 months-a recommended alternative to 9 months of isoniazid for therapy of latent tuberculosis infection. In an open-label randomized trial at a university-affiliated respiratory hospital, consenting patients whose treating physician had recommended therapy for latent tuberculosis infection were randomized to daily self-administered rifampin for 4 months or daily self-administered isoniazid for 9 months. Of 58 patients randomized to rifampin, 53 (91%) took 80% of doses, and 50 (86%) took more than 90% of doses within 20 weeks compared with 44 (76%) and 36 (62%) who took 80 and 90%, respectively, of doses of isoniazid within 43 weeks (relative risks: 80% of doses, 1.2 [95% confidence interval: 1.02, 1.4]; 90% of doses, 1.4 [1.1, 1.7]). Adverse events resulted in permanent discontinuation of therapy for two (3%) patients taking rifampin, and for eight (14%) patients taking isoniazid. Three patients developed drug-induced hepatitis--all were taking isoniazid. Total costs of therapy were significantly higher for isoniazid. In conclusion, completion of therapy was significantly better with 4 months of rifampin and major side effects were somewhat lower. Further studies are needed to assess the safety and efficacy of the 4-month rifampin regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Cited by
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
Menzies, D., Adjobimey, M., Ruslami, R., Trajman, A., Sow, O., Kim, H., Obeng Baah, J., Marks, G. B., Long, R., Hoeppner, V., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714283 · Cited by 383
Self-citationLatent Tuberculosis Infection in the United States
Horsburgh, C. R., & Rubin, E. J. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1005750 · Cited by 311
Updates on the risk factors for latent tuberculosis reactivation and their managements
Ai, J.-W., Ruan, Q.-L., Liu, Q.-H., & Zhang, W.-H. (2016) · Emerging Microbes & Infections · doi:10.1038/emi.2016.10 · Cited by 298
Spyridis, N. P., Spyridis, P. G., Gelesme, A., Sypsa, V., Valianatou, M., Metsou, F., Gourgiotis, D., & Tsolia, M. N. (2007) · Clinical Infectious Diseases · doi:10.1086/520983 · Cited by 259
Antituberculosis drugs and hepatotoxicity
YEW, W. W., & LEUNG, C. C. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00941.x · Cited by 256
Metadata
- Authors
- Menzies, D., Dion, M.-J., Rabinovitch, B., Mannix, S., Brassard, P., & Schwartzman, K.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-15
- Volume
- 170
- Issue
- 4
- Pages
- 445-449
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2130324392
- Cited by
- 168
- References
- 1
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months. https://app.cochat.ai/papers/10.1164/rccm.200404-478oc
- The paper
- Menzies, D., Dion, M.-J., Rabinovitch, B., Mannix, S., Brassard, P., & Schwartzman, K. (2004). Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200404-478oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.